APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurological Disorder Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurological Disorder Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025180 pages

Choose your research edition.

Industry ResearchNeurological Disorder Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurological Disorder Drugs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Neurological Disorder Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurological Disorder Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurological Disorder Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neurological Disorder Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurological Disorder Drugs include Boehringer Ingelheim, Teva Pharmaceutical, AstraZeneca, Bayer, GlaxoSmithKline, Merck & Co. and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neurological Disorder Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurological Disorder Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurological Disorder Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neurological Disorder Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurological Disorder Drugs Segment by Company

Boehringer Ingelheim

Teva Pharmaceutical

AstraZeneca

Bayer

GlaxoSmithKline

Merck & Co.

Novartis

Neurological Disorder Drugs Segment by Type

Analgesics

Anticoagulants

Antipsychotic

Hypnotic & Sedative

Others

Neurological Disorder Drugs Segment by Application

Hospital

Clinic

Neurological Disorder Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Disorder Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurological Disorder Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Disorder Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neurological Disorder Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurological Disorder Drugs industry.

Chapter 3: Detailed analysis of Neurological Disorder Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurological Disorder Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurological Disorder Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Analgesics Table 3. Key Players of Anticoagulants Table 4. Key Players of Antipsychotic Table 3. Key Players of Hypnotic & Sedative Table 4. Key Players of Others Table 5. Global Neurological Disorder Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospital Table 7. Key Players of Clinic Table 8. Global Neurological Disorder Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Neurological Disorder Drugs Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Neurological Disorder Drugs Market Share by Region (2021-2026) Table 11. Global Neurological Disorder Drugs Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Neurological Disorder Drugs Market Share by Region (2027-2032) Table 13. Neurological Disorder Drugs Industry Trends Table 14. Neurological Disorder Drugs Industry Drivers Table 15. Neurological Disorder Drugs Industry Opportunities and Challenges Table 16. Neurological Disorder Drugs Industry Restraints Table 17. Global Neurological Disorder Drugs Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Neurological Disorder Drugs Revenue Market Share by Company (2021-2026) Table 19. Global Neurological Disorder Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Neurological Disorder Drugs Key Company Head Office and Area Served Table 21. Global Neurological Disorder Drugs Company, Product Type & Application Table 22. Global Neurological Disorder Drugs Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Neurological Disorder Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Neurological Disorder Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Neurological Disorder Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Neurological Disorder Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Neurological Disorder Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Neurological Disorder Drugs Revenue Market Share by Application (2027-2032) Table 35. Boehringer Ingelheim Company Information Table 36. Boehringer Ingelheim Business Overview Table 37. Boehringer Ingelheim Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Boehringer Ingelheim Neurological Disorder Drugs Product Portfolio Table 39. Boehringer Ingelheim Recent Development Table 40. Teva Pharmaceutical Company Information Table 41. Teva Pharmaceutical Business Overview Table 42. Teva Pharmaceutical Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio Table 44. Teva Pharmaceutical Recent Development Table 45. AstraZeneca Company Information Table 46. AstraZeneca Business Overview Table 47. AstraZeneca Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. AstraZeneca Neurological Disorder Drugs Product Portfolio Table 49. AstraZeneca Recent Development Table 50. Bayer Company Information Table 51. Bayer Business Overview Table 52. Bayer Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bayer Neurological Disorder Drugs Product Portfolio Table 54. Bayer Recent Development Table 55. GlaxoSmithKline Company Information Table 56. GlaxoSmithKline Business Overview Table 57. GlaxoSmithKline Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. GlaxoSmithKline Neurological Disorder Drugs Product Portfolio Table 59. GlaxoSmithKline Recent Development Table 60. Merck & Co. Company Information Table 61. Merck & Co. Business Overview Table 62. Merck & Co. Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Merck & Co. Neurological Disorder Drugs Product Portfolio Table 64. Merck & Co. Recent Development Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Novartis Neurological Disorder Drugs Product Portfolio Table 69. Novartis Recent Development Table 70. North America Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 71. North America Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 72. North America Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 73. North America Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 74. North America Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Neurological Disorder Drugs Market Size by Country (2021-2026) Table 76. North America Neurological Disorder Drugs Market Size by Country (2027-2032) Table 77. Europe Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 78. Europe Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 79. Europe Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 80. Europe Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 81. Europe Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Europe Neurological Disorder Drugs Market Size by Country (2021-2026) Table 83. Europe Neurological Disorder Drugs Market Size by Country (2027-2032) Table 84. China Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 85. China Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 86. China Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 87. China Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 88. Asia Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 89. Asia Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 90. Asia Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 91. Asia Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Asia Neurological Disorder Drugs Market Size by Country (2021-2026) Table 94. Asia Neurological Disorder Drugs Market Size by Country (2027-2032) Table 95. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Type (2021-2026) & (US$ Million) Table 96. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Type (2027-2032) & (US$ Million) Table 97. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Application (2021-2026) & (US$ Million) Table 98. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Application (2027-2032) & (US$ Million) Table 99. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2021-2026) Table 101. South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2027-2032) Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Neurological Disorder Drugs Product Image Figure 2. Global Neurological Disorder Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neurological Disorder Drugs Market Share by Type: 2025 VS 2032 Figure 4. Analgesics Image Figure 5. Anticoagulants Image Figure 6. Antipsychotic Image Figure 7. Hypnotic & Sedative Image Figure 8. Others Image Figure 9. Global Neurological Disorder Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Neurological Disorder Drugs Market Share by Application: 2025 VS 2032 Figure 11. Hospital Image Figure 12. Clinic Image Figure 13. Global Neurological Disorder Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 15. Global Neurological Disorder Drugs Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Neurological Disorder Drugs Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Neurological Disorder Drugs Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Neurological Disorder Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neurological Disorder Drugs Revenue Market Share by Type (2021-2032) Figure 22. Global Neurological Disorder Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neurological Disorder Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 25. North America Neurological Disorder Drugs Market Share by Type (2021-2032) Figure 26. North America Neurological Disorder Drugs Market Share by Application (2021-2032) Figure 27. North America Neurological Disorder Drugs Market Share by Country (2021-2032) Figure 28. United States Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 29. Canada Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Europe Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neurological Disorder Drugs Market Share by Type (2021-2032) Figure 33. Europe Neurological Disorder Drugs Market Share by Application (2021-2032) Figure 34. Europe Neurological Disorder Drugs Market Share by Country (2021-2032) Figure 35. Germany Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 36. France Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 38. Italy Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Russia Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 41. China Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 42. China Neurological Disorder Drugs Market Share by Type (2021-2032) Figure 43. China Neurological Disorder Drugs Market Share by Application (2021-2032) Figure 44. Asia Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 45. Asia Neurological Disorder Drugs Market Share by Type (2021-2032) Figure 46. Asia Neurological Disorder Drugs Market Share by Application (2021-2032) Figure 47. Asia Neurological Disorder Drugs Market Share by Country (2021-2032) Figure 48. Japan Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 52. India Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 53. Australia Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neurological Disorder Drugs Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Neurological Disorder Drugs Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Neurological Disorder Drugs Market Share by Country (2021-2032) Figure 58. Brazil Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 63. UAE Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Chile Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Analgesics
  • Anticoagulants
  • Antipsychotic
  • Hypnotic & Sedative
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • Boehringer Ingelheim
  • Teva Pharmaceutical
  • AstraZeneca
  • Bayer
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Analgesics
  5. 1.2.3 Anticoagulants
  6. 1.2.4 Antipsychotic
  7. 1.2.5 Hypnotic & Sedative
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Clinic
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Neurological Disorder Drugs Growth Trends by Region
  15. 1.5.1 Global Neurological Disorder Drugs Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Neurological Disorder Drugs Market Size by Region (2021-2026)
  17. 1.5.3 Neurological Disorder Drugs Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Neurological Disorder Drugs Market Dynamics
  1. 2.1 Neurological Disorder Drugs Industry Trends
  2. 2.2 Neurological Disorder Drugs Industry Drivers
  3. 2.3 Neurological Disorder Drugs Industry Opportunities and Challenges
  4. 2.4 Neurological Disorder Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neurological Disorder Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Neurological Disorder Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neurological Disorder Drugs Key Company Head office and Area Served
  4. 3.4 Global Neurological Disorder Drugs Company, Product Type & Application
  5. 3.5 Global Neurological Disorder Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neurological Disorder Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neurological Disorder Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neurological Disorder Drugs Tier 1, Tier 2, and Tier 3
4 Neurological Disorder Drugs Market by Type
  1. 4.1 Global Neurological Disorder Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neurological Disorder Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Neurological Disorder Drugs Market Size Share by Type (2021-2032)
5 Neurological Disorder Drugs Market by Application
  1. 5.1 Global Neurological Disorder Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurological Disorder Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Neurological Disorder Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Boehringer Ingelheim
  2. 6.1.1 Boehringer Ingelheim Company Information
  3. 6.1.2 Boehringer Ingelheim Business Overview
  4. 6.1.3 Boehringer Ingelheim Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Boehringer Ingelheim Neurological Disorder Drugs Product Portfolio
  6. 6.1.5 Boehringer Ingelheim Recent Developments
  7. 6.2 Teva Pharmaceutical
  8. 6.2.1 Teva Pharmaceutical Company Information
  9. 6.2.2 Teva Pharmaceutical Business Overview
  10. 6.2.3 Teva Pharmaceutical Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio
  12. 6.2.5 Teva Pharmaceutical Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 AstraZeneca Neurological Disorder Drugs Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Bayer
  20. 6.4.1 Bayer Company Information
  21. 6.4.2 Bayer Business Overview
  22. 6.4.3 Bayer Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Bayer Neurological Disorder Drugs Product Portfolio
  24. 6.4.5 Bayer Recent Developments
  25. 6.5 GlaxoSmithKline
  26. 6.5.1 GlaxoSmithKline Company Information
  27. 6.5.2 GlaxoSmithKline Business Overview
  28. 6.5.3 GlaxoSmithKline Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 GlaxoSmithKline Neurological Disorder Drugs Product Portfolio
  30. 6.5.5 GlaxoSmithKline Recent Developments
  31. 6.6 Merck & Co.
  32. 6.6.1 Merck & Co. Company Information
  33. 6.6.2 Merck & Co. Business Overview
  34. 6.6.3 Merck & Co. Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Merck & Co. Neurological Disorder Drugs Product Portfolio
  36. 6.6.5 Merck & Co. Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis Neurological Disorder Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Novartis Neurological Disorder Drugs Product Portfolio
  42. 6.7.5 Novartis Recent Developments
7 North America
  1. 7.1 North America Neurological Disorder Drugs Market Size (2021-2032)
  2. 7.2 North America Neurological Disorder Drugs Market Size by Type
  3. 7.2.1 North America Neurological Disorder Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Neurological Disorder Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Neurological Disorder Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Neurological Disorder Drugs Market Size by Application
  7. 7.3.1 North America Neurological Disorder Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Neurological Disorder Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Neurological Disorder Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Neurological Disorder Drugs Market Size by Country
  11. 7.4.1 North America Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neurological Disorder Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Neurological Disorder Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Neurological Disorder Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neurological Disorder Drugs Market Size (2021-2032)
  2. 8.2 Europe Neurological Disorder Drugs Market Size by Type
  3. 8.2.1 Europe Neurological Disorder Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neurological Disorder Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neurological Disorder Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Neurological Disorder Drugs Market Size by Application
  7. 8.3.1 Europe Neurological Disorder Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neurological Disorder Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neurological Disorder Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Neurological Disorder Drugs Market Size by Country
  11. 8.4.1 Europe Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neurological Disorder Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neurological Disorder Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neurological Disorder Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neurological Disorder Drugs Market Size (2021-2032)
  2. 9.2 China Neurological Disorder Drugs Market Size by Type
  3. 9.2.1 China Neurological Disorder Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Neurological Disorder Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Neurological Disorder Drugs Market Share by Type (2021-2032)
  6. 9.3 China Neurological Disorder Drugs Market Size by Application
  7. 9.3.1 China Neurological Disorder Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Neurological Disorder Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Neurological Disorder Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neurological Disorder Drugs Market Size (2021-2032)
  2. 10.2 Asia Neurological Disorder Drugs Market Size by Type
  3. 10.2.1 Asia Neurological Disorder Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neurological Disorder Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neurological Disorder Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Neurological Disorder Drugs Market Size by Application
  7. 10.3.1 Asia Neurological Disorder Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neurological Disorder Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neurological Disorder Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Neurological Disorder Drugs Market Size by Country
  11. 10.4.1 Asia Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neurological Disorder Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neurological Disorder Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neurological Disorder Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neurological Disorder Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neurological Disorder Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neurological Disorder Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neurological Disorder Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neurological Disorder Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst